New hope for incurable germ cell tumors? cabozantinib trial underway
NCT ID NCT04876456
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing the drug cabozantinib in 50 patients with germ cell tumors that have not responded to standard chemotherapy. The goal is to see if the drug can stop or slow tumor growth. Patients take cabozantinib daily until the disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cabozantinib
- What this could lead to
- If successful, this could offer a new treatment option for patients with germ cell tumors that have not responded to standard chemotherapy.
- What could go wrong
- This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. The drug can cause side effects, and it may not shrink tumors or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- High-Dose chemo with stem cell transplant tested against standard therapy for tough germ cell cancers
- Could a dementia drug shield kids' brains from radiation damage?
- Dietary change explored as cancer support strategy
- Hypnosis may ease chemo anxiety in teens and young adults
- New proton beam study aims to cut cancer treatment side effects
- Could a simple pill keep relapsed testicular cancer at bay?